The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Allergan Generics

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

International Medical Group, Inc.

Advised International Medical Group, Inc., a leader in the global insurance and assistance services market, on its sale to ABRY Partners

Aesynt, Inc.

Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems

Allied Healthcare

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

Heartland Payment Systems, Inc.

Advised Heartland Payment Systems, Inc., one of the nation’s largest payment companies, on its sale to Global Payments Inc., a leading worldwide provider of payment technology services

11 Private Equity Fund Positions Managed by NBGI Private Equity and Team’s Spinout

Advised the National Bank of Greece SA, the leading bank in Greece by deposits and total assets, on the disposal of 100% of its interests in eleven funds managed by NBGI Private Equity. The management responsibility of the funds and underlying investments will continue to be performed by the current management team along with other persons appointed by the buyers, under a new management vehicle created expressly for this purpose

Policard

Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world

Boehringer Ingelheim

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

Total Care Medicaid Plan

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

Elavon do Brasil

Advised Minneapolis-based US Bancorp, the fifth largest commercial bank in the United States, and the parent company of Elavon, Inc., in the sale of its 50.1 percent majority stake in São Paulo-based, Elavon do Brasil to Stone Pagamentos, a local market, privately-held merchant acquirer.

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

Aegerion Pharmaceuticals

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

US rights to an authorized generic version of Adderall XR

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR

US rights to 37 approved and 5 pipeline generic products

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

BioD, LLC

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

Gradifi, Inc.

Advised First Republic Bank, a provider of private banking, private business banking and private wealth management services, on the acquisition of Gradifi, a Boston-based technology and service platform used by employers to make direct contributions to employees’ student loans

LCH.Clearnet SA

Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated

Wells Fargo Share Registration & Service business

Advised Equiniti Group plc, a UK based specialist technology outsourcer providing non-discretionary payment and administration services, on the acquisition of Wells Fargo's Shareowner Services business, and acted as joint sponsor to Equiniti's associated £122 million rights issue